PharmaCyte Biotech, Inc. 4

What Happened
The Form 4 filed for FEMASYS (FEMY) reports that the reporting person's beneficial ownership fell below the 10% threshold as of the reporting period ending March 17, 2026. The filing states that, as a result, the reporting person is no longer subject to Section 16 obligations and "will no longer report any such transactions on Form 4 or Form 5." The filing includes no specific share counts, prices, or transaction values in the provided remark.

Key Details

• Filing date: 2026-03-18; Period of report: 2026-03-17.
• Primary statement: beneficial ownership fell below 10%, ending Section 16 reporting obligations for this reporting person.
• No transaction quantities, prices, or proceeds are disclosed in the supplied remark. Check the full Form 4 for any earlier transaction lines that may explain how the ownership changed (sale, gift, or dilution).
• No indication in the provided text that this filing was late.

Context
Falling below 10% removes the requirement for a shareholder to file under Section 16 (which covers officers, directors and >10% owners). This statement does not itself indicate a purchase or sale — the reduction in ownership could result from a sale, gift, or dilution (e.g., new shares issued). For investors wanting to see whether shares were sold, review prior and contemporaneous Form 4 filings from the same reporting person for transaction details.